GlaxoSmithKline : Corporate Governance And Section 172 Statements For Applicable UK Subsidiaries PDF - 104.2KB

Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the ViiV's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above

ViiV Healthcare Limited

1

Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Glaxo Operations UK Limited

GlaxoSmithKline UK Limited

GlaxoSmithKline Research & Development Limited

ViiV Healthcare Trading Services UK Limited

GlaxoSmithKline Intellectual Property Limited

GlaxoSmithKline Intellectual Property (No.2) Limited

GlaxoSmithKline Export Limited

GlaxoSmithKline Consumer Trading Services Limited

GlaxoSmithKline Services Unlimited

GlaxoSmithKline Consumer Healthcare (Overseas) Limited

Dealcyber Limited

Glaxo Group Limited

GlaxoSmithKline Caribbean Limited

GlaxoSmithKline Consumer Healthcare (UK) Trading Limited

ViiV Healthcare UK Limited

ViiV Healthcare UK (No.3) Limited

GlaxoSmithKline UK Limited

GlaxoSmithKline Mercury Limited

GlaxoSmithKline Holdings (Ireland) Limited

SmithKline Beecham Research Limited

2

Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above.

GlaxoSmithKline Consumer Healthcare Finance No.2 Limited

GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited

GlaxoSmithKline Consumer Healthcare Sri Lanka Holdings Limited

PRISM PCH Limited

3

Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the TESARO UK Limited's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above.

Tesaro UK Limited

4

Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

GlaxoSmithKline Consumer Healthcare (UK) IP Limited

PHIVCO UK II Limited

BEECHAM GROUP P L C

Galvani Bioelectronics Limited

Wellcome Limited

ViiV Healthcare Overseas Limited

Stiefel Consumer Healthcare (UK) Limited

SmithKline Beecham Overseas Limited

SmithKline Beecham Limited

SmithKline Beecham (H) Limited

PHIVCO UK II Limited

Horlicks Limited

GlaxoSmithKline Consumer Healthcare Holdings Limited

GlaxoSmithKline Holdings (One) Limited

GlaxoSmithKline Holdings Limited

GlaxoSmithKline Intellectual Property Development Limited

GlaxoSmithKline Intellectual Property Holdings Limited

GlaxoSmithKline Intellectual Property Management Limited

5